LYON, France–(BUSINESS WIRE)–Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today announces its revenue for the third quarter ended September 30, 2026, and for the first nine months of the fiscal year. Commercial Activity Update T